Business Wire

CA-ARIA-SYSTEMS

9.8.2022 13:02:07 CEST | Business Wire | Press release

Share
Aria Systems to Showcase TM Forum Catalyst Solution at Digital Transformation World

Aria Systems , the leader in helping enterprises grow subscription and usage-based revenue, today announced the company will be at Digital Transformation World (DTW) in September to present the findings and solution resulting from its involvement in one of TM Forum’s most championed catalyst programs. Aria and its partners have been exploring how an event-driven architecture can enable service providers to build more scalable and flexible IT architecture with lower integration costs, and faster time to market.

Catalysts are proof-of-concept projects developed collaboratively by members to solve problems presented by leading global communications service providers (CSPs) and define and propose new industry standards. Together with its partners and CSP champions, Aria will demonstrate how the Open Digital Framework (ODF) can be enhanced for organizations that have adopted a modern event-driven architecture.

“As CSPs transform their BSS solution with best-of-breed capabilities to support new opportunities delivered by software-defined networks, zero-touch automation, and cloud partnerships, their ecosystems grow in complexity,” said Brendan O’Brien, Aria Co-founder and Chief Innovation Officer. “While the TM Forum Open API and ODA standards have helped ease integration burdens, loosely coupled event-based architectures, such as those adopted by the internet industry, are proving more nimble and scalable. The catalyst team at DTW will demonstrate how existing TM Forum APIs can be enhanced for an event-based architecture with additional standardized patterns to ensure robustness and assurance in service delivery, orchestration, and monetization.”

In April, Aria became a founding participant in the catalyst entitled “Async Open APIs for Event-Based Architectures,” championed by BT, Jio, Orange, Telenor, Verizon, Vodafone, and lead champion CityFibre. Aria has been working alongside CPQ vendor Bit2win and systems integrators EPAM, TechMahindra, and Yupiik to demonstrate how, as operators move from large BSS/OSS systems to a best-of-breed ODA framework, open APIs can be converted and extended to support an event-based architecture, enabling greater flexibility and faster time to market for dynamic and growing ecosystems and partnerships.

“In addition to meeting the specific challenges posed by our CSP champions, the results of the catalyst also demonstrate how Aria’s open architecture philosophy natively supports this technical transformation journey, delivering significant impact and benefits in terms of speed and cost,” O’Brien continued.

Aria will present the results of the catalyst alongside partners during a theater presentation at DTW, taking place in Copenhagen from September 20-22. The company will also demonstrate the solution in the TM Forum catalyst booth and at its DTW booth (#304).

About Aria Systems:
Aria Systems’ native public cloud monetization platform is the analysts’ choice, top ranked by leading research firms. Innovative enterprises like Adobe, Comcast, Liberty Latin America, Subaru, and Telstra depend on Aria to accelerate time to market and increase flexibility, enabling them to maximize customer value, and grow recurring revenue through subscription, usage-based, and one-time offerings. For more information, visit: www.ariasystems.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye